Dreamy Delivery Announced as the Official Delivery Platform of the 2021 Emerald Cup Awards

The Hollister -owned platform will allow NorCal consumers to participate in the virtual global event

 Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the " Company ", " Hollister Cannabis Co. " or " Hollister ") is pleased to announce that its direct-to-consumer delivery platform, Dreamy Delivery, will be the official delivery platform of the 2021 Emerald Cup Awards.  Dreamy Delivery will feature prominently in all Emerald Cup promotions and coverage, and it will help connect Bay Area, Sacramento Hollister and Central Coast consumers with the brands participating in the virtual awards this April.

"The Emerald Cup Awards have been the premier Cannabis Cup in California for 17 years. It is a huge part of the fabric of cannabis in Northern California . We are excited and honored to be the official delivery platform of The Emerald Cup Awards," says Carl Saling , the Co-Founder, CEO and Director of Hollister Biosciences.

"We're excited to have Dreamy Delivery as our sponsor for this year's Emerald Cup. We share the same values of vetting only the best cannabis products, best business practices, supporting social equity and offering a 5-Star experience. We are honored collaborating together this year." ~Tim Blake, Founder of The Emerald Cup

For the first time in Emerald Cup history, the awards will be a virtual global event streaming on the Social Club TV network. Whether NoCal consumers want to sample the brands taking home the top trophies or try past winners, Dreamy Delivery brings these best-in-class products directly to their front doors utilizing all of the recommended safety protocols. This means virtual participants can experience the 17th-annual event with actual winning products delivered directly and safely to their homes.

As the official delivery platform for the awards, Dreamy Delivery will feature prominently in a six-month promotion that includes social media posts, newsletters, PR statements and brand placement in the title card and afterparty.

The Emerald Cup Awards (described as the "Academy Awards of Cannabis" by Rolling Stone ) celebrate the best emerging and established brands, and a slate of hand-picked judges selects winners that are announced daily during Take Over Week ahead of the official awards celebration. The coverage will culminate in the Social Club TV-broadcasted ceremony on Sunday, April 11, 2021 with the top honors given out in the prestigious cannabis flower categories.

About The Emerald Cup

The Emerald Cup is Northern California's premier cannabis destination. While advancing the concept of sustainable, outdoor farming, its reputation is firmly solidified as the largest, most respected, outdoor cannabis competition in the world. As a group, The Emerald Cup prides itself in bringing together experts and educators in the cannabis industry to our fellow farmers, patients, and patrons each year.

It is a community celebration that has grown to become a global movement honoring the year's finest, organic, sun-grown, cannabis harvest.

https://theemeraldcup.com/

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high-margin model that controls the whole process from manufacture to sales to distribution for what's best described as seed-to-shelf cannabis. Products from Hollister Biosciences Inc. include HashBone, the brand's premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly owned California subsidiary Hollister Cannabis Co is the first state and locally licensed cannabis company in the city of Hollister, California , birthplace of the "American Biker."

Website:   www.hollistercannabisco.co   m , https://dreamydelivery.com/

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed "forward-looking statements". The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "would", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/dreamy-delivery-announced-as-the-official-delivery-platform-of-the-2021-emerald-cup-awards-301242689.html

SOURCE Hollister Biosciences Inc.

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Highlights:

  • Screening closed for all sites and final participants being scheduled for dosing
  • On track for top-line 6-week primary endpoint results in late Q2

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Highlights:

  • 52-week observational follow-up study from Phase 2b reveals single 25 mg COMP360 psilocybin dose offers longer-term antidepressant effects compared to lower doses, with average efficacy for a single dose of 25mg lasting about 12 weeks and substantially longer in a subgroup
  • Findings published in the March edition of the Journal of Clinical Psychiatry

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Compass Pathways to Participate in Stifel Virtual CNS Forum

Compass Pathways to Participate in Stifel Virtual CNS Forum

COMPASS Pathways Plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel Virtual CNS Forum at 11:30 am ET on March 18 th , 2025.

A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
AVECHO BIOTECHNOLOGY

Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia

Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia. Avecho retains the rights to commercialise the product in all other territories, with Sandoz granted a first right of refusal for these markets. Avecho’s CBD capsule aims to be the first pharmaceutical CBD product registered with the Therapeutic Goods Administration (“TGA”) as an over-the-counter medicine, which market forecasts predict could generate sales surpassing US$125M per annum in Australia2.

Keep reading...Show less

Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the TD Cowen 45 th Annual Health Care Conference at 1:10 pm ET on March 3 rd , 2025.

A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass management will host a conference call at 8:00 am ET (1:00pm UK)

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×